Virtual Library

Start Your Search

H. Park

Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      48P - Clinical characteristics of Korean lung cancer patients with programmed death-ligand 1 expression (ID 301)

      12:30 - 13:00  |  Presenting Author(s): H. Park

      • Abstract

      Programmed death-ligand 1 (PD-L1) is a transmembrane protein binds to the programmed death-1 (PD-1) receptor and anti-PD-1 therapy enables the immune response against tumors. The aim of this study was to assess the clinical and pathologic characteristics of PD-L1 positive lung cancer patients in Korea.

      We retrospectively reviewed the clinical data of pathologically proven lung cancer patients, and collected 267 cases of formalin-fixed, paraffin-embedded tissue sample from single institution. PD-L1 expression was detected by immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3. PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), the percentage of viable tumor cells showing partial or complete membrane staining. The specimen should be considered PD-L1 positive as TPS ≥ 50% of tumor cells. We categorized according to the percentage of TPS; more than 1% or 50%.

      A total of 267 patients were enrolled and major histologic types were adenocarcinoma (ADC)(69.3%). The majority was smoker (67.4%) and clinical stage IV (60.7%). 31 (11.6%) cases of EGFR mutation and 17 (6.4%) cases of ALK FISH positive were included. The patients who showed TPS ≥ 1% and 50% were 116 (42%) and 58 (21%), respectively. More than 1% of TPS group was older than below (64.83 ± 9.38 vs. 61.73 ± 10.78, p = 0.014). More than 1% of TPS group was consisted of ADC (67.8%) and squamous cell carcinoma(SqC) (29.6%) histology. And more than 50% of TPS group was composed of ADC (72.4%), SqC (22.4%). More than 1% of TPS group was significantly older than less (64.83 ± 9.38 years vs. 61.73 ± 10.78 years, p = 0.014). The rate of poorly differentiated pathology was significantly higher in TPS ≥ 1% group (42(40.8%) vs. 32(25.8%)) and TPS ≥ 50% group (25(53.2%) vs. 49(27.2%)). There was no difference in smoking, EGFR mutation, ALK rearrangement status or biopsy site.

      In Korean lung cancer patients, PD-L1 positive group defined as TPS ≥ 1% was older than negative group. And major histology was poorly differentiated non-small cell lung cancer in both TPS ≥ 1% and 50% groups.

      Clinical trial identification:

      Legal entity responsible for the study:
      Chonnam National University Hospital, Hwasun

      Has not received any funding

      The author has declared no conflicts of interest.